Commissioner Gottlieb's resignation: What does this mean for Pharma?

3 April 2019

By Dr Nicola Davies

The immediate response of the pharmaceutical industry to the resignation of US Food and Drug Administration Commissioner Dr Scott Gottlieb on March 5, 2019, was one of shock. Biotech stocks plummeted. IBB, an exchange-traded fund that tracks some of the biggest names in biotech, fell by more than 2%. Amgen, Gilead Sciences, and Biogen initially registered the largest individual declines, all falling by more than 2% in the immediate aftermath of the announcement.1 Why was Pharma quite so unsettled by the sudden resignation of a Commissioner who has been notably vocal in his criticism of some industry practices?

Commissioner Gottlieb takes the helm

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK